The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.
Open accessAbstract
Treatment effects on bone quality and remodeling was assessed in postmenopausal women with osteoporosis treated with oral alendronate. One transiliac bone biopsy was obtained from 231 women at either 24 mo (n = 11) or 36 mo (n = 120) from the start of treatment with alendronate at doses of between 5 and 20 mg/d, or placebo. 64 biopsies at 24 mo (31 from the placebo group and 33 alendronate-treated patients) and 95 biopsies at 36 mo (40 from the placebo group and 55 alendronate-treated patients) provided adequate cancellous tissue, and were analyzed by histomorphometry. Mineral apposition rate was unaffected by treatment. At 24 and 36 mo, osteoid thickness, volume, and surface significantly decreased. At each of the doses studied, mineralizing surface and activation frequency significantly decreased at each time point (e.g., -92% and -87%, respectively, for the 10 mg daily dose after 2 yr). These diminutions were of the same magnitude for each dose at 24 mo, and for the two highest doses at 36 mo. A significant increase in wall thickness accompanied by a reduction in erosion depth was detected in biopsies obtained at 24 mo. These findings confirm that mineralization is normal, and trabecular bone turnover markedly decreased in patients receiving long-term dosing with alendronate. The findings also suggest that the observed increases in bone mineral density could result both from a reduction in the remodeling space due to a decreased activation frequency and a possible trend to a positive bone balance. In addition, further studies focused on a possible increase in the degree of mineralization of bone are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Self-citationBone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Self-citationBone density at various sites for prediction of hip fractures
Cummings, S. R., Browner, W., Cummings, S. R., Black, D. M., Nevitt, M. C., Browner, W., Genant, H. K., Cauley, J., Ensrud, K., Scott, J., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92555-8 · Cited by 2,446
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Garnero, P. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.79.6.1693 · Cited by 707
Fleisch, H. (1991) · Drugs · doi:10.2165/00003495-199142060-00003 · Cited by 581
Testing the Statistical Certainty of a Response to Increasing Doses of a Drug
Tukey, J. W., Ciminera, J. L., & Heyse, J. F. (1985) · Biometrics · doi:10.2307/2530666 · Cited by 486
Balena, R., Toolan, B. C., Shea, M., Markatos, A., Myers, E. R., Lee, S. C., Opas, E. E., Seedor, J. G., Klein, H., & Frankenfield, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116872 · Cited by 396
Chesnut, C. H., McClung, M. R., Ensrud, K. E., Bell, N. H., Genant, H. K., Harris, S. T., Singer, F. R., Stock, J. L., Yood, R. A., Delmas, P. D., et al. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80134-x · Cited by 365
Parfitt, A. M., Mundy, G. R., Roodman, G. D., Hughes, D. E., & Boyce, B. F. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110203 · Cited by 336
Effects of bisphosphonates on isolated Rat osteoclasts as examined by reflected light microscopy
Sato, M., & Grasser, W. (1990) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650050107 · Cited by 264
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone
Siris, E. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.3.961 · Cited by 227
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
Tucci, J. R., Tonino, R. P., Emkey, R. D., Peverly, C. A., Kher, U., & Santora, A. C. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00282-3 · Cited by 220
Osteomalacia and Related Disorders
Parfitt, A. M. (1998) · Metabolic Bone Disease and Clinically Related Disorders · doi:10.1016/b978-012068700-8/50012-8 · Cited by 204
FOCAL OSTEOMALACIA DUE TO LOW-DOSE DIPHOSPHONATE THERAPY IN PAGET'S DISEASE
Boyce, B. F., Fogelman, I., Ralston, S., Smith, L., Johnston, E., & Boyle, I. T. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92272-4 · Cited by 196
Devogelaer, J. P., Broll, H., Correa-Rotter, R., Cumming, D. C., Nagant de Deuxchaisnes, C., Geusens, P., Hosking, D., Jaeger, P., Kaufman, J. M., Leite, M., et al. (1996) · Bone · doi:10.1016/8756-3282(95)00436-x · Cited by 191
Self-citationEriksen, E. F., Gundersen, H. J. G., Melsen, F., & Mosekilde, L. (1984) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(84)90066-3 · Cited by 190
Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women1
Bone, H. G., Downs, R. W., Tucci, J. R., Harris, S. T., Weinstein, R. S., Licata, A. A., McClung, M. R., Kimmel, D. B., Gertz, B. J., Hale, E., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3682 · Cited by 189
Harris, S. T. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.6.1399 · Cited by 182
Reid, I. R., Nicholson, G. C., Weinstein, R. S., Hosking, D. J., Cundy, T., Kotowicz, M. A., Murphy, W. A., Yeap, S., Dufresne, S., Lombardi, A., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00227-6 · Cited by 178
Rosen, H. N., Dresner-Pollak, R., Moses, A. C., Rosenblatt, M., Zeind, A. J., Clemens, J. D., & Greenspan, S. L. (1994) · Calcified Tissue International · doi:10.1007/bf00316285 · Cited by 165
Adámi, S., Passeri, M., Ortolani, S., Broggini, M., Carratelli, L., Caruso, I., Gandolini, G., Gnessi, L., Laurenzi, M. W., Lombardi, A., et al. (1995) · Bone · doi:10.1016/s8756-3282(95)00262-6 · Cited by 142
Self-citationAntiresorptive dose-response relationships across three generations of bisphosphonates.
Sietsema, W. K., Ebetino, F. H., Salvagno, A. M., & Bevan, J. A. (1989) · PubMed · Cited by 139
Expansion of the medullary cavity at the expense of cortex in postmenopausal osteoporosis
Keshawarz, N. M., & Recker, R. R. (1984) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(84)90063-8 · Cited by 120
Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women
Bone, H. G. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.1.265 · Cited by 114
Lafage‐Proust, M., Balena, R., Battle, M. A., Shea, M., Seedor, J. G., Klein, H. J., Hayes, W. C., & Rodan, G. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117901 · Cited by 111
Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis
Rossini, M., Gatti, D., Zamberlan, N., Braga, V., Dorizzi, R. M., & Adámi, S. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091121 · Cited by 106
Cohen-Solal, M. E., Shih, M., Lundy, M. W., & Parfitt, M. A. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650061210 · Cited by 93
New bisphosphonates in osteoporosis
Fleisch, H. A. (1993) · Osteoporosis International · doi:10.1007/bf01623222 · Cited by 91
Rationale for the use of alendronate in osteoporosis
Kanis, J. А., Gertz, B. J., Singer, F. R., & Ortolani, S. (1995) · Osteoporosis International · doi:10.1007/bf01623652 · Cited by 89
Kragstrup, J., Gundersen, H. J. G., Melsen, F., & Mosekilde, L. (1982) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(82)90024-8 · Cited by 88
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1996) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199604000-00018 · Cited by 81
Preclinical pharmacology of alendronate
Rodan, G. A., Seedor, J. G., & Balena, R. (1993) · Osteoporosis International · doi:10.1007/bf01623001 · Cited by 67
Adámi, S., Baroni, M. C., Broggini, M., Carratelli, L., Caruso, I., Gnessi, L., Laurenzi, M. W., Lombardi, A., Norbiato, G., Ortolani, S., et al. (1993) · Osteoporosis International · doi:10.1007/bf01623004 · Cited by 65
Self-citationChavassieux, P., ARLOT, M. E., & Meunier, P. J. (1985) · Bone · doi:10.1016/8756-3282(85)90004-3 · Cited by 61
Self-citationBisphosphonates: A New Class of Drugs in Diseases of Bone and Calcium Metabolism
Fleisch, H. A. (1988) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-71806-9_21 · Cited by 58
Balena, R., Markatos, A., Seedor, J. G., Gentile, M., Stark, C., Peter, C. P., & Rodan, G. A. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12262-3 · Cited by 39
Capizzi, T. P., Survill, T. T., Heyse, J. F., & Malani, H. M. (1992) · Biometrical Journal · doi:10.1002/bimj.4710340303 · Cited by 32
&NA; (1996) · The Endocrinologist · doi:10.1097/00019616-199605000-00025 · Cited by 19
Black, D., Cummings, S. R., & Thompson, D. E. (1996) · Osteoporosis International · doi:10.1007/bf02499914 · Cited by 7
Cited by
Manolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Meunier, P. J., Roux, C., Seeman, E., Ortolani, S., Badurski, J. E., Spector, T. D., Cannata, J., Balogh, A., Lemmel, E.-M., Pors-Nielsen, S., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa022436 · Cited by 1,638
Self-citationSeverely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Metadata
- Authors
- Chavassieux, P. M., Arlot, M. E., Reda, C., Wei, L., Yates, A. J., & Meunier, P. J.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-09-15
- Volume
- 100
- Issue
- 6
- Pages
- 1475-1480
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2023781848
- Cited by
- 523
- References
- 41
- FWCI
- 14.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.